Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Research & Development: 2021-2024

Historic Research & Development for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $19.6 million.

  • ARS Pharmaceuticals' Research & Development fell 37.80% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 36.04%. This contributed to the annual value of $19.6 million for FY2024, which is 3.38% down from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Research & Development is $19.6 million, which was down 3.38% from $20.3 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Research & Development registered a high of $20.3 million during FY2021, and its lowest value of $18.4 million during FY2022.
  • In the last 3 years, ARS Pharmaceuticals' Research & Development had a median value of $19.6 million in 2024 and averaged $19.4 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Research & Development dropped by 9.36% in 2022, and later climbed by 10.29% in 2023.
  • ARS Pharmaceuticals' Research & Development (Yearly) stood at $20.3 million in 2021, then declined by 9.36% to $18.4 million in 2022, then climbed by 10.29% to $20.3 million in 2023, then declined by 3.38% to $19.6 million in 2024.